{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T02:41:22Z","timestamp":1769308882362,"version":"3.49.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s40360-016-0056-y","type":"journal-article","created":{"date-parts":[[2016,2,24]],"date-time":"2016-02-24T20:35:15Z","timestamp":1456346115000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Cefepime shows good efficacy and no antibiotic resistance in pneumonia caused by Serratia marcescens and Proteus mirabilis \u2013 an observational study"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8363-621X","authenticated-orcid":false,"given":"Josef","family":"Yayan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beniam","family":"Ghebremedhin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kurt","family":"Rasche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,3,23]]},"reference":[{"issue":"suppl 1","key":"56_CR1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000196242","volume":"60","author":"G H\u00f6ffken","year":"1993","unstructured":"H\u00f6ffken G. Clinical requirements in the treatment of today\u2019s respiratory tract infections. Respiration. 1993;60 suppl 1:3\u20139.","journal-title":"Respiration"},{"key":"56_CR2","first-page":"198","volume":"12","author":"D Koulenti","year":"2006","unstructured":"Koulenti D, Rello J. Gram-negative bacterial pneumonia: aetiology and management. Curr Opin Pulm Med. 2006;12:198\u2013204.","journal-title":"Curr Opin Pulm Med"},{"key":"56_CR3","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1055\/s-0028-1119810","volume":"30","author":"MI Restrepo","year":"2009","unstructured":"Restrepo MI, Anzueto A. The role of gram-negative bacteria in healthcare-associated pneumonia. Semin Respir Crit Care Med. 2009;30:61\u20136.","journal-title":"Semin Respir Crit Care Med"},{"key":"56_CR4","unstructured":"GlobalRPh. Gram Negative Bacteria, Gram-Negative Cocci & Coccobacilli, Non-fermenting Gram-negative bacilli, Anaerobic Gram-Negative Bacilli. 2013. http:\/\/www.globalrph.com\/bacterial-strains-gram-negative.htm . Accessed 2 March 2015."},{"key":"56_CR5","first-page":"88","volume":"90","author":"WW Wong","year":"1991","unstructured":"Wong WW, Wang LS, Cheng DL, Lin SJ, Chin TD, Hinthorn DR, et al. Serratia marcescens bacteremia. J Formos Med Assoc. 1991;90:88\u201393.","journal-title":"J Formos Med Assoc"},{"key":"56_CR6","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s10096-010-1135-4","volume":"30","author":"G Samonis","year":"2011","unstructured":"Samonis G, Vouloumanou EK, Christofaki M, Dimopoulou D, Maraki S, Triantafyllou E, et al. Serratia infections in a general hospital: characteristics and outcomes. Eur J Clin Microbiol Infect Dis. 2011;30:653\u201360.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"56_CR7","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1128\/CMR.13.4.534-546.2000","volume":"13","author":"CM O\u2019Hara","year":"2000","unstructured":"O\u2019Hara CM, Brenner FW, Miller JM. Classification, identification, and clinical significance of Proteus, Providencia, and Morganella. Clin Microbiol Rev. 2000;13:534\u201346.","journal-title":"Clin Microbiol Rev"},{"key":"56_CR8","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s10156-010-0059-3","volume":"16","author":"N Okimoto","year":"2010","unstructured":"Okimoto N, Hayashi T, Ishiga M, Nanba F, Kishimoto M, Yagi S, et al. Clinical features of Proteus mirabilis pneumonia. J Infect Chemother. 2010;16:364\u20136.","journal-title":"J Infect Chemother"},{"key":"56_CR9","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s10096-014-2067-1","volume":"33","author":"A Torres","year":"2014","unstructured":"Torres A, Blasi F, Peetermans WE, Viegi G, Welte T. The aetiology and antibiotic management of community-acquired pneumonia in adults in Europe: a literature review. Eur J Clin Microbiol Infect Dis. 2014;33:1065\u201379.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"56_CR10","doi-asserted-by":"crossref","first-page":"20s","DOI":"10.1183\/09031936.02.00702002","volume":"36","author":"M Woodhead","year":"2002","unstructured":"Woodhead M. Community-acquired pneumonia in Europe: causative pathogens and resistance patterns. Eur Respir J Suppl. 2002;36:20s\u20137.","journal-title":"Eur Respir J Suppl"},{"key":"56_CR11","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/S1473-3099(14)70828-X","volume":"14","author":"A Zumla","year":"2014","unstructured":"Zumla A, Memish ZA, Maeurer M, Bates M, Mwaba P, Al-Tawfig JA, et al. Emerging novel and antimicrobial-resistant respiratory tract infections: new drug development and therapeutic options. Lancet Infect Dis. 2014;14:1136\u201349.","journal-title":"Lancet Infect Dis"},{"key":"56_CR12","unstructured":"World Health Organization (WHO). International classification of diseases (ICD). http:\/\/www.who.int\/classification\/icd\/en\/ . Accessed 2 March 2015."},{"key":"56_CR13","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1164\/ajrccm.163.7.at1010","volume":"163","author":"MS Niederman","year":"2001","unstructured":"Niederman MS, Mandell LA, Anzeuto A, Bass JB, Groughton WA, Campbell GD, et al. American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001;163:1730\u201354.","journal-title":"Am J Respir Crit Care Med"},{"key":"56_CR14","first-page":"1299","volume":"83","author":"RR Watkins","year":"2011","unstructured":"Watkins RR, Lemonovich TL. Diagnosis and management of community-acquired pneumonia in adults. Am Fam Physician. 2011;83:1299\u2013306.","journal-title":"Am Fam Physician"},{"key":"56_CR15","unstructured":"Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. CLSI M100-S22. Clinical and Laboratory Standards Institute, Wayne, Pad; 2012."},{"key":"56_CR16","unstructured":"European committee on antimicrobial susceptibility testing (EUCAST) breakpoints 2011\u20132014. http:\/\/www.eucast.org . Accessed 2 March 2015."},{"key":"56_CR17","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/ajcp\/45.4_ts.493","volume":"45","author":"AW Bauer","year":"1966","unstructured":"Bauer AW, Kirby WM, Sherris JC, Turck M. Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol. 1966;45:493\u20136.","journal-title":"Am J Clin Pathol"},{"key":"56_CR18","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0272-5231(21)00471-8","volume":"8","author":"JG Barlett","year":"1987","unstructured":"Barlett JG. Diagnosis of bacterial infections of the lung. Clin Chest Med. 1987;8:119\u201334.","journal-title":"Clin Chest Med"},{"key":"56_CR19","unstructured":"VassarStats [website for statistical computation] and Concepts & Applications of Inferential Statistics [companion textbook]. http:\/\/vassarstats.net\/ and http:\/\/vassarstats.net\/textbook\/ . Accessed 2 March 2015."},{"key":"56_CR20","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1159\/000085614","volume":"51","author":"H Tumah","year":"2005","unstructured":"Tumah H. Fourth-generation cephalosporins: in vitro activity against nosocomial gram-negative bacilli compared with beta-lactam antibiotics and ciprofloxacin. Chemotherapy. 2005;51:80\u20135.","journal-title":"Chemotherapy"},{"key":"56_CR21","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1093\/jac\/dki335","volume":"56","author":"DS Burgess","year":"2005","unstructured":"Burgess DS, Frei CR. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics\/pharmacodynamics. J Antimicrob Chemother. 2005;56:893\u20138.","journal-title":"J Antimicrob Chemother"},{"key":"56_CR22","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1128\/AAC.02780-13","volume":"58","author":"AB Montgomery","year":"2014","unstructured":"Montgomery AB, Rhomberg PR, Abuan T, Walters KA, Flamm RK. Potentiation effects of amikacin and fosfomycin against selected amikacin-nonsusceptible Gram-negative respiratory tract pathogens. Antimicrob Agents Chemother. 2014;58:3714\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"56_CR23","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1177\/0885066605278650","volume":"20","author":"DL Green","year":"2005","unstructured":"Green DL. Selection of an empiric antibiotic regimen for hospital-acquired pneumonia using a unit and culture-type specific antibiogram. J Intensive Care Med. 2005;20:296\u2013301.","journal-title":"J Intensive Care Med"},{"key":"56_CR24","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/BF03256641","volume":"2","author":"TM Chapman","year":"2003","unstructured":"Chapman TM, Perry CM. Cefepime: a review of its use in the management of hospitalized patients with pneumonia. Am J Respir Med. 2003;2:75\u2013107.","journal-title":"Am J Respir Med"},{"key":"56_CR25","doi-asserted-by":"crossref","first-page":"e732","DOI":"10.1016\/j.ijid.2011.07.007","volume":"15","author":"AS Michalopoulos","year":"2011","unstructured":"Michalopoulos AS, Livaditis IG, Gougoutas V. The revival of fosfomycin. Int J Infect Dis. 2011;15:e732\u20139.","journal-title":"Int J Infect Dis"},{"key":"56_CR26","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/jac\/dkr466","volume":"67","author":"DE Karageorgopoulos","year":"2012","unstructured":"Karageorgopoulos DE, Wang R, Yu XH, Falagas ME. Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens. J Antimicrob Chemother. 2012;67:255\u201368.","journal-title":"J Antimicrob Chemother"},{"key":"56_CR27","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1086\/527442","volume":"46","author":"ME Falagas","year":"2008","unstructured":"Falagas ME, Giannopoulou KP, Kokolakis GN, Rafailidis PI. Fosfomycin: use beyond urinary tract and gastrointestinal infections. Clin Infect Dis. 2008;46:1069\u201377.","journal-title":"Clin Infect Dis"},{"key":"56_CR28","doi-asserted-by":"crossref","first-page":"4943","DOI":"10.1128\/AAC.00296-11","volume":"55","author":"KM Papp-Wallace","year":"2011","unstructured":"Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA. Carbapenems: past, present, and future. Antimicrob Agents Chemother. 2011;55:4943\u201360.","journal-title":"Antimicrob Agents Chemother"},{"key":"56_CR29","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2165\/00003495-200868060-00006","volume":"68","author":"CM Baldwin","year":"2008","unstructured":"Baldwin CM, Lyseng-Williamson KA, Keam SJ. Meropenem: a review of its use in the treatment of serious bacterial infections. Drugs. 2008;68:803\u201338.","journal-title":"Drugs"},{"key":"56_CR30","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.2165\/00003495-200363240-00008","volume":"63","author":"KF Croom","year":"2003","unstructured":"Croom KF, Goa KL. Levofloxacin: a review of its use in the treatment of bacterial infections in the United States. Drugs. 2003;63:2769\u2013802.","journal-title":"Drugs"},{"key":"56_CR31","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0149-2918(03)80091-7","volume":"25","author":"M West","year":"2003","unstructured":"West M, Boulanger BR, Fogarty C, Tennenberg A, Wiesinger B, Oross M, et al. Levofloxacin compared with imipenem\/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized, open-label study. Clin Ther. 2003;25:485\u2013506.","journal-title":"Clin Ther"},{"key":"56_CR32","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/ja.2008.35","volume":"61","author":"K Yamaguchi","year":"2008","unstructured":"Yamaguchi K, Ishii Y, Yamanaka K, Watanabe N, Uehara N, Kaku M, et al. [Nationwide susceptibility surveillance of ciprofloxacin and various parenteral antimicrobials against bacteria isolated from patients with severe infections\u2014third ciproxan injection special survey (2005)]. Jpn J Antibiot. 2008;61:241\u201368 [Article in Japanese].","journal-title":"Jpn J Antibiot"},{"key":"56_CR33","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s10156-004-0364-9","volume":"11","author":"N Okimoto","year":"2005","unstructured":"Okimoto N, Yamato K, Honda Y, Kurihara T, Osaki K, Asaoka N, et al. Clinical effect of intravenous ciprofloxacin on hospital-acquired pneumonia. J Infect Chemother. 2005;11:52\u20134.","journal-title":"J Infect Chemother"},{"key":"56_CR34","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jfma.2013.10.002","volume":"113","author":"C Chen","year":"2014","unstructured":"Chen C, Chen Y, Wu P, Chen B. Update on new medicinal applications of gentamicin: evidence-based review. J Formos Med Assoc. 2014;113:72\u201382.","journal-title":"J Formos Med Assoc"},{"key":"56_CR35","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1517\/14656566.2012.721777","volume":"13","author":"SH Choi","year":"2012","unstructured":"Choi SH, Koh Y. Ceftazidime for respiratory infections. Expert Opin Pharmacother. 2012;13:2097\u2013109.","journal-title":"Expert Opin Pharmacother"},{"key":"56_CR36","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1586\/14787210.5.3.365","volume":"5","author":"A Gin","year":"2007","unstructured":"Gin A, Dilay L, Karlowsky JA, Walkty A, Rubinstein E, Zhanel GG. Piperacillin-tazobactam: a beta-lactam\/beta-lactamase inhibitor combination. Expert Rev Anti Infect Ther. 2007;5:365\u201383.","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"suppl 1","key":"56_CR37","first-page":"3","volume":"8","author":"P Periti","year":"1996","unstructured":"Periti P. [Tobramycin\u2014clinical pharmacology and chemotherapy]. J Chemother. 1996;8 suppl 1:3\u201330 [Article in Italian].","journal-title":"J Chemother"},{"key":"56_CR38","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/S0025-6196(12)62478-1","volume":"66","author":"FR Cockerill","year":"1991","unstructured":"Cockerill FR, Edson RS. Trimethoprim-sulfamethoxazole. Mayo Clin Proc. 1991;66:1260\u20139.","journal-title":"Mayo Clin Proc"},{"key":"56_CR39","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2165\/00019053-199813010-00009","volume":"13","author":"GL Plosker","year":"1998","unstructured":"Plosker GL, Foster RH, Benfield P. Cefotaxime. A pharmacoeconomic review of its use in the treatment of infections. Pharmacoeconomics. 1998;13:91\u2013106.","journal-title":"Pharmacoeconomics"},{"key":"56_CR40","doi-asserted-by":"crossref","first-page":"C539","DOI":"10.1152\/ajpcell.00047.2010","volume":"299","author":"MO Griffin","year":"2010","unstructured":"Griffin MO, Fricovsky E, Ceballos G, Villareal F. Tetracyclines: a pleitropic family of compounds with promising therapeutic properties. Review of the literature. Am J Physiol Cell Physiol. 2010;299:C539\u201348.","journal-title":"Am J Physiol Cell Physiol"},{"key":"56_CR41","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2165\/00003495-198428050-00002","volume":"28","author":"B Holmes","year":"1984","unstructured":"Holmes B, Richards DM, Brogden RN, Heel RC. Piperacillin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1984;28:375\u2013425.","journal-title":"Drugs"},{"key":"56_CR42","first-page":"13","volume":"32","author":"R Ergova","year":"2000","unstructured":"Ergova R, K\u2018oleian E, Kharalambieva I, Mitov I, Docheva LU. [A comparative study of antibacterial activity of ceftibuten, ceftazidime, cefuroxime and ampicillin against clinical isolates]. Vutr Boles. 2000;32:13\u20137 [Article in Bulgarian].","journal-title":"Vutr Boles"},{"key":"56_CR43","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.2165\/00003495-200161100-00008","volume":"61","author":"LJ Scott","year":"2001","unstructured":"Scott LJ, Ormrod D, Goa KL. Cefuroxime axetil: an updated review of its use in the management of bacterial infections. Drugs. 2001;61:1455\u2013500.","journal-title":"Drugs"},{"key":"56_CR44","first-page":"ME01","volume":"8","author":"D Kaushik","year":"2014","unstructured":"Kaushik D, Mohan M, Borade DM, Swami OC. Ampicillin: rise fall and resurgence. Clin Diagn Res. 2014;8:ME01\u20133.","journal-title":"Clin Diagn Res"},{"key":"56_CR45","doi-asserted-by":"crossref","first-page":"290","DOI":"10.4065\/74.3.290","volume":"74","author":"AJ Wright","year":"1999","unstructured":"Wright AJ. The penicillins. Mayo Clin Proc. 1999;74:290\u2013307.","journal-title":"Mayo Clin Proc"},{"key":"56_CR46","first-page":"173","volume":"4","author":"MA Dominguez","year":"1998","unstructured":"Dominguez MA, Pallares R. Antibiotic resistance in respiratory pathogens. Curr Opin Pulm Med. 1998;4:173\u20139.","journal-title":"Curr Opin Pulm Med"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-016-0056-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,5]],"date-time":"2022-06-05T02:01:36Z","timestamp":1654394496000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.biomedcentral.com\/2050-6511\/17\/10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,23]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["56"],"URL":"https:\/\/doi.org\/10.1186\/s40360-016-0056-y","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,23]]},"article-number":"10"}}